Chemokine mutants acting as chemokine antagonists

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/19 (2006.01) A61K 38/19 (2006.01) A61P 29/00 (2006.01) A61P 35/00 (2006.01) A61P 37/00 (2006.01) C07K 14/52 (2006.01) C12N 15/63 (2006.01) C12P 21/02 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2468790

Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2 , 3, or 4.

L'invention concerne des mutants de chimiokines CC spécifiques contenant une substitution non persistante dans une séquence consensus conservée, lesquels mutants agissent en tant qu'antagonistes de chimiokines CC et peuvent être utilisés de manière efficace dans le traitement de maladies auto-immunes et inflammatoires, de cancers, et d'infection virales ou bactériennes. Les mutants privilégiés dans cette invention sont les mutants RANTES/CCL5 comprenant la séquence d'acides aminés représentée par SEQ ID NO: 1, 2, 3, or 4.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Chemokine mutants acting as chemokine antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chemokine mutants acting as chemokine antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine mutants acting as chemokine antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1580312

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.